Dr. Juha K. Rantala is the founder and principal investigator of Misvik Biology Ltd (Turku, Finland). Dr. Rantala received his PhD in biomedical engineering with invention of the Cell Spot Microarray (CSMA) technology. He has a deep scientific pedigree in the molecular profiling of human cancers and has previously worked as a research professor at Knight Cancer Institute, Oregon Health and Science University, as a lecturer at University of Sheffield, Department of Oncology and Metabolism and currently also as Target Identification Lead for oncology research at Orion Pharma. He has 20+ years of experience on high throughput in vitro an ex vivo drug screening technologies for cancer research and drug development. Since 2015 under guidance of Dr. Rantala, Misvik Biology has been pioneering a functional diagnostic ex vivo therapy efficacy assessment platform for rare solid cancers and assay technologies for characterization and grouping of engineered nanomaterials based on toxicogenomics.